UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
13D
(Amendment
No. 1)
Under
the Securities Exchange Act of 1934
KIWA
BIO-TECH PRODUCTS GROUP CORPORATION
(Name
of Issuer)
Common
Stock, par value $0.001 per share
(Title
of Class of Securities)
49834X
205
(CUSIP
Number)
Wei
Li
310
N. Indian Hill Blvd., #702
Claremont,
California 91711
(626)
715-5855
(Name,
Address and Telephone Number of Person Authorized to
Receive
Notices and Communications)
June
15, 2016
(Date
of Event which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ]
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however,
see
the Notes).
1
|
NAME
OF REPORTING PERSON
Wei
Li
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)
[ ]
(b)
[ ]
|
3
|
SEC
USE ONLY
|
4
|
SOURCE
OF FUNDS*
OO
|
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
[ ]
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Peoples
Republic of China
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
1,965,324
|
8
|
SHARED
VOTING POWER
0
|
9
|
SOLE
DISPOSITIVE POWER
1,965,324
|
10
|
SHARED
DISPOSITIVE POWER
0
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON
1,965,324
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[ ]
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
37.32%
|
14
|
TYPE
OF REPORTING PERSON (See Instructions)
IN
|
|
|
|
|
Item
1. Security and Issuer.
This
amended statement (“Statement”) relates to shares of common stock, par value $0.001 per share (the “Common Stock”),
of Kiwa Bio-Tech Products Group Corporation, a Delaware corporation (the “Issuer” or the “Company”). The
principal executive office of the Issuer is located at 310 N. Indian Hill Blvd., #702, Claremont, California 91711. On June 15,
2016, the reporting person transferred 1,000,000 share of company
common stock to Troniya Industrial Inqubator Co. Ltd.
The reporting person received no consideration for this transfer.
Item
2. Identity and Background
The
Statement is being filed by Wei Li (“Mr. Li”) with an address at 310 N. Indian Hill Blvd, Claremont, CA 91711. Mr.
Li’s United States address is 310 N. Indian Hill Blvd., #702, Claremont, California 91711. Mr. Li is a citizen of the Peoples
Republic of China.
During
the last five years Mr. Li has not (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors);
or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which
proceeding he was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating
activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item
3. Source and Amount of Funds or Other Consideration.
Mr.
Li acquired 2,965,324 shares of the Company’s common stock as follows:
(a)
|
All
Star Technology, Inc., a British Virgin Island company acquired 61,784 shares of Company common stockprior to 2007. Wei Li
is a principal stockholder of All Star Technology, Inc. and may be deemed to beneficially own such shares;
|
|
|
(b)
|
Mr.
Li acquired 3,541 shares of Company common stock individually prior to 2007;
|
|
|
(c)
|
On
April 1, 2016, Mr. Li converted $2,900,000 of Company convertible debentures into 2,900,000 shares of Company common stock.
|
On
June 15, the reporting person transferred 1,000,000 share of company
common stock to Troniya Industrial Inqubator Co. Ltd.
The reporting person received no consideration for this transfer.
Item
4. Purpose of Transaction.
Mr.
Li does not have any current plans or proposals which relate to or would result in: (a) the acquisition by Mr. Li of additional
securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as
a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material
amount of assets of the Issuer or any of its subsidiaries; (d) any change in the present board of directors or management of the
Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;
(e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer’s
business or corporate structure; (g) any change in the Issuer’s charter, bylaws or instruments corresponding thereto or
other actions which may impede the acquisition of control of the Issuer by any person; (h) causing a class of securities of the
Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation
system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination
of registration pursuant to section 12(g)(4) of the Exchange Act; or (j) any action similar to any of those enumerated above.
Item
5. Interest in Securities of the Issuer.
(a)
As of the date hereof, Mr. Li beneficially owns 1,965,324 shares of the issued and outstanding common stock of the Company. Such
amount represents 37.32% of the total issued and outstanding shares of the Company’s common stock as of the date hereof.
(b)
Mr. Li holds sole voting and dispositive power over the Shares.
(c)
Other than disclosed below, there were no transactions by Mr. Li in the Issuer’s Common Stock during the last 60 days:
none.
(d)
No other person is known to have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds
from the sale of, the securities of the Issuer owned by Mr. Li.
(e)
Not applicable.
Item
6. Contracts, Agreements, Understandings or Relationships With Respect to Securities of the Issuer.
To
the knowledge of Mr. Li, there are no contracts, arrangements, understandings or relationships (legal or otherwise), including
but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements,
puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies between Mr. Li and/or
any other person, with respect to any securities of the Company.
Item
7. Material to be Filed as Exhibits.
Not
applicable.
SIGNATURES
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Date:
June 20, 2016
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Apr 2023 to Apr 2024